These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36803310)

  • 1. Tocilizumab Versus Baricitinib for the Treatment of COVID-19 in Patients With Obesity.
    Troyer BS; Kovacic Scherrer N; Garavaglia J
    J Pharm Pract; 2024 Jun; 37(3):632-636. PubMed ID: 36803310
    [No Abstract]   [Full Text] [Related]  

  • 2. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pronounced benefits of JAK inhibition with baricitinib in COVID-19 pneumonia in obese but not lean subjects.
    David P; Hen O; Ben-Shabbat N; Macleod T; Amital H; Watad A; McGonagle DG
    RMD Open; 2024 May; 10(2):. PubMed ID: 38796180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baricitinib versus tocilizumab in critically ill COVID-19 patients: A retrospective cohort study.
    Conroy GM; Bauer SR; Pallotta AM; Duggal A; Wang L; Sacha GL
    Pharmacotherapy; 2024 Jan; 44(1):28-38. PubMed ID: 37593883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baricitinib versus tocilizumab in mechanically ventilated patients with COVID-19: a nationwide cohort study.
    You SH; Baek MS; Kim TW; Jung SY; Kim WY
    Crit Care; 2024 Aug; 28(1):282. PubMed ID: 39210469
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial.
    Ely EW; Ramanan AV; Kartman CE; de Bono S; Liao R; Piruzeli MLB; Goldman JD; Saraiva JFK; Chakladar S; Marconi VC;
    Lancet Respir Med; 2022 Apr; 10(4):327-336. PubMed ID: 35123660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficacy and adverse events of baricitinib treatment for coronavirus disease-2019 (COVID-19): A systematic review and meta-analysis.
    Lin Z; Niu J; Xu Y; Qin L; Ding J; Zhou L
    J Med Virol; 2022 Apr; 94(4):1523-1534. PubMed ID: 34846766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Efficacy of Tocilizumab and Baricitinib Administration in COVID-19 Treatment: A Retrospective Cohort Study.
    Kojima Y; Nakakubo S; Takei N; Kamada K; Yamashita Y; Nakamura J; Matsumoto M; Horii H; Sato K; Shima H; Suzuki M; Konno S
    Medicina (Kaunas); 2022 Apr; 58(4):. PubMed ID: 35454352
    [No Abstract]   [Full Text] [Related]  

  • 9. Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID-19 pneumonia: A retrospective analysis.
    Pérez-Alba E; Nuzzolo-Shihadeh L; Aguirre-García GM; Espinosa-Mora J; Lecona-Garcia JD; Flores-Pérez RO; Mendoza-Garza M; Camacho-Ortiz A
    J Microbiol Immunol Infect; 2021 Oct; 54(5):787-793. PubMed ID: 34294593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baricitinib and Pulse Steroids Combination Treatment in Hyperinflammatory COVID-19: A Rheumatological Approach in the Intensive Care Unit.
    Ferro F; La Rocca G; Elefante E; Italiano N; Moretti M; Talarico R; Pelati E; Valentini K; Baldini C; Mozzo R; De Simone L; Mosca M
    Int J Mol Sci; 2024 Jul; 25(13):. PubMed ID: 39000379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of high dose of baricitinib in severe COVID-19 pneumonia: a prospective cohort study in Bangladesh.
    Hasan MJ; Rabbani R; Anam AM; Huq SMR; Polash MMI; Nessa SST; Bachar SC
    BMC Infect Dis; 2021 May; 21(1):427. PubMed ID: 33962573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined administration of inhaled DNase, baricitinib and tocilizumab as rescue treatment in COVID-19 patients with severe respiratory failure.
    Gavriilidis E; Antoniadou C; Chrysanthopoulou A; Ntinopoulou M; Smyrlis A; Fotiadou I; Zioga N; Kogias D; Natsi AM; Pelekoudas C; Satiridou E; Bakola SA; Papagoras C; Mitroulis I; Peichamperis P; Mikroulis D; Papadopoulos V; Skendros P; Ritis K
    Clin Immunol; 2022 May; 238():109016. PubMed ID: 35447311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study.
    Bryushkova EA; Skatova VD; Mutovina ZY; Zagrebneva AI; Fomina DS; Kruglova TS; Akopyan AA; Strazhesko ID; Lukyanov SA; Tkacheva ON; Lysenko MA; Chudakov DM
    PLoS One; 2022; 17(8):e0273340. PubMed ID: 36001576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.
    Marconi VC; Ramanan AV; de Bono S; Kartman CE; Krishnan V; Liao R; Piruzeli MLB; Goldman JD; Alatorre-Alexander J; de Cassia Pellegrini R; Estrada V; Som M; Cardoso A; Chakladar S; Crowe B; Reis P; Zhang X; Adams DH; Ely EW;
    Lancet Respir Med; 2021 Dec; 9(12):1407-1418. PubMed ID: 34480861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study.
    Rodriguez-Garcia JL; Sanchez-Nievas G; Arevalo-Serrano J; Garcia-Gomez C; Jimenez-Vizuete JM; Martinez-Alfaro E
    Rheumatology (Oxford); 2021 Jan; 60(1):399-407. PubMed ID: 33020836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secondary infections and long-term outcomes among hospitalized elderly and non-elderly patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and treated with baricitinib: a comparative study from the national centre of Hungary.
    Gáspár Z; Szabó BG; Andrikovics H; Ceglédi A; Rajmon M; Ábrahám A; Várnai Z; Kiss-Dala N; Szlávik J; Sinkó J; Vályi-Nagy I; Lakatos B
    Geroscience; 2024 Jun; 46(3):2863-2877. PubMed ID: 38367195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.
    Kalil AC; Patterson TF; Mehta AK; Tomashek KM; Wolfe CR; Ghazaryan V; Marconi VC; Ruiz-Palacios GM; Hsieh L; Kline S; Tapson V; Iovine NM; Jain MK; Sweeney DA; El Sahly HM; Branche AR; Regalado Pineda J; Lye DC; Sandkovsky U; Luetkemeyer AF; Cohen SH; Finberg RW; Jackson PEH; Taiwo B; Paules CI; Arguinchona H; Erdmann N; Ahuja N; Frank M; Oh MD; Kim ES; Tan SY; Mularski RA; Nielsen H; Ponce PO; Taylor BS; Larson L; Rouphael NG; Saklawi Y; Cantos VD; Ko ER; Engemann JJ; Amin AN; Watanabe M; Billings J; Elie MC; Davey RT; Burgess TH; Ferreira J; Green M; Makowski M; Cardoso A; de Bono S; Bonnett T; Proschan M; Deye GA; Dempsey W; Nayak SU; Dodd LE; Beigel JH;
    N Engl J Med; 2021 Mar; 384(9):795-807. PubMed ID: 33306283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe COVID-19.
    Izumo T; Kuse N; Awano N; Tone M; Sakamoto K; Takada K; Muto Y; Fujimoto K; Saiki A; Ito Y; Matsumoto H; Inomata M
    Respir Investig; 2021 Nov; 59(6):799-803. PubMed ID: 34413006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes of immunomodulation therapy in immunocompromised patients with severe Covid-19 and high oxygen requirement.
    Goldstein A; Neuberger A; Darawsha YQ; Hussein K; Shafat T; Grupel D; Strahilevitz J; Israel S; Weil A; Ben-Ami R; Elbaz M; Najjar-Debbiny R; Bishara J; Shlomai A; Landes M
    Sci Rep; 2024 Jul; 14(1):16985. PubMed ID: 39044026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experience With the Use of Baricitinib and Tocilizumab Monotherapy or Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus COVID19: A Real-World Study.
    Rosas J; Liaño FP; Cantó ML; Barea JMC; Beser AR; Rabasa JTA; Adsuar FM; Auli BV; López IF; Sainz AMG; Ramis PE; Pérez LR; Rebollo MLN; Lorido RH; Escolar LG;
    Reumatol Clin (Engl Ed); 2022 Mar; 18(3):150-156. PubMed ID: 35277213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.